JP2026000916A5 - - Google Patents
Info
- Publication number
- JP2026000916A5 JP2026000916A5 JP2025140269A JP2025140269A JP2026000916A5 JP 2026000916 A5 JP2026000916 A5 JP 2026000916A5 JP 2025140269 A JP2025140269 A JP 2025140269A JP 2025140269 A JP2025140269 A JP 2025140269A JP 2026000916 A5 JP2026000916 A5 JP 2026000916A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- pharmaceutically acceptable
- substituted
- compound according
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343959P | 2022-05-19 | 2022-05-19 | |
| US63/343,959 | 2022-05-19 | ||
| JP2024568561A JP7735594B2 (ja) | 2022-05-19 | 2023-05-19 | アザ四環式オキサゼピン化合物及びその使用 |
| PCT/US2023/022914 WO2023225302A1 (en) | 2022-05-19 | 2023-05-19 | Aza-tetracyclic oxazepine compounds and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024568561A Division JP7735594B2 (ja) | 2022-05-19 | 2023-05-19 | アザ四環式オキサゼピン化合物及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026000916A JP2026000916A (ja) | 2026-01-06 |
| JP2026000916A5 true JP2026000916A5 (cg-RX-API-DMAC7.html) | 2026-05-22 |
Family
ID=86895902
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024568561A Active JP7735594B2 (ja) | 2022-05-19 | 2023-05-19 | アザ四環式オキサゼピン化合物及びその使用 |
| JP2025140269A Pending JP2026000916A (ja) | 2022-05-19 | 2025-08-26 | アザ四環式オキサゼピン化合物及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024568561A Active JP7735594B2 (ja) | 2022-05-19 | 2023-05-19 | アザ四環式オキサゼピン化合物及びその使用 |
Country Status (17)
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020020307A2 (pt) | 2018-04-04 | 2021-01-12 | Arvinas Operations, Inc. | Moduladores de proteólise e métodos de uso associados |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| CN115557974A (zh) * | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CN119365467A (zh) | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| TW202409051A (zh) * | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| AU2023320565A1 (en) | 2022-08-05 | 2025-01-23 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| PE20260006A1 (es) | 2023-01-26 | 2026-01-06 | Arvinas Operations Inc | Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| EP4716531A2 (en) * | 2023-05-22 | 2026-04-01 | Board of Regents, The University of Texas System | Heterocyclic compounds as nras inhibitors |
| WO2025006967A1 (en) | 2023-06-30 | 2025-01-02 | Bristol-Myers Squibb Company | Kras inhibitors |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| WO2025045141A1 (en) * | 2023-08-31 | 2025-03-06 | Suzhou Zanrong Pharma Limited | Kras inhibitors and uses thereof |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| TW202540122A (zh) * | 2023-11-22 | 2025-10-16 | 美商建南德克公司 | Kras-g12d之氮雜-四環氧氮呯抑制劑的多晶型物及合成方法 |
| WO2025123007A1 (en) * | 2023-12-08 | 2025-06-12 | Kestrel Therapeutics Inc. | Ras inhibitors and methods of use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025194134A1 (en) | 2024-03-15 | 2025-09-18 | Genentech, Inc. | Linearly substituted oxazepin-5-one kras-g12d inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026011344A1 (en) * | 2024-07-10 | 2026-01-15 | Nikang Therapeutics, Inc. | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| TW202615038A (zh) | 2024-08-07 | 2026-04-16 | 美商太斯萊特醫藥美國有限責任公司 | 包含拓樸異構酶有效載荷之靶向kras之共價誘導之藥物結合物 |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026039659A1 (en) * | 2024-08-14 | 2026-02-19 | Board Of Regents, The University Of Texas System | Heterocyclic compounds as ras inhibitors |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026073024A1 (en) * | 2024-09-30 | 2026-04-02 | Gilead Sciences, Inc. | Kras g12d inhibitors for the treatment of cancer |
| WO2026080548A1 (en) | 2024-10-10 | 2026-04-16 | Genentech, Inc. | Method of treating cancer using the kras g12d inhibitor gcd-7035 |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
| CN121108144B (zh) * | 2025-09-02 | 2026-07-03 | 领泰生物医药(绍兴)有限公司 | 一种含氮杂多环化合物的制备方法及其中间体 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| WO2020097537A2 (en) | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| CN114615981B (zh) * | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| CN116867792A (zh) | 2021-02-09 | 2023-10-10 | 基因泰克公司 | 四环氧氮杂䓬化合物及其用途 |
| US20240199644A1 (en) * | 2021-03-07 | 2024-06-20 | Jacobio Pharmaceuticals Co., Ltd. | Fused Ring Derivatives Useful as KRAS G12D Inhibitors |
| CN117043167A (zh) * | 2021-03-17 | 2023-11-10 | 劲方医药科技(上海)有限公司 | 嘧啶并环类化合物及其制法和用途 |
| CN117083281A (zh) * | 2021-03-24 | 2023-11-17 | 南京明德新药研发有限公司 | 嘧啶并杂环类化合物及其应用 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| MX2023015533A (es) * | 2021-06-21 | 2024-01-23 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto tetraciclico fusionado, metodo de preparacion y aplicacion en medicina. |
| CN115557974A (zh) | 2021-07-02 | 2023-01-03 | 上海迪诺医药科技有限公司 | Kras g12d抑制剂及其应用 |
| CN117677624A (zh) * | 2021-07-19 | 2024-03-08 | 上海艾力斯医药科技股份有限公司 | 新型吡啶并嘧啶衍生物 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| WO2023018812A1 (en) | 2021-08-10 | 2023-02-16 | Amgen Inc. | Heterocyclic compounds and methods of use |
| JP2024532735A (ja) | 2021-08-10 | 2024-09-10 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| TW202315626A (zh) | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| WO2023030495A1 (en) | 2021-09-03 | 2023-03-09 | Ascentage Pharma (Suzhou) Co., Ltd. | Kras inhibitors |
| CN118019746A (zh) | 2021-09-27 | 2024-05-10 | 北京加科思新药研发有限公司 | 多环稠环衍生物及其用途 |
| CN116199703A (zh) | 2021-12-01 | 2023-06-02 | 江苏恒瑞医药股份有限公司 | 稠合四环杂环化合物、其制备方法及其在医药上的应用 |
| WO2023103906A1 (zh) | 2021-12-07 | 2023-06-15 | 贝达药业股份有限公司 | Kras g12d抑制剂及其在医药上的应用 |
| CN116332948A (zh) | 2021-12-22 | 2023-06-27 | 翰森生物有限责任公司 | 一种含氮四环化合物及其制备方法和药用用途 |
| JP2025504041A (ja) | 2022-01-30 | 2025-02-06 | シャンハイ ファーマシューティカルズ ホールディング カンパニー,リミティド | キノリン系化合物及びその使用 |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AU2023265688A1 (en) | 2022-05-06 | 2024-10-17 | PAQ Therapeutics Inc. | Kras g12d proteolysis targeting chimeras |
| CN119365467A (zh) | 2022-05-19 | 2025-01-24 | 基因泰克公司 | 氮杂-四环氧氮杂䓬化合物及其用途 |
| TW202409051A (zh) | 2022-07-27 | 2024-03-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠環類化合物、其製備方法及其在醫藥上的應用 |
| CN117462688A (zh) | 2022-07-28 | 2024-01-30 | 江苏恒瑞医药股份有限公司 | 一种包含kras g12d抑制剂的组合物 |
| KR20250037564A (ko) | 2022-07-29 | 2025-03-17 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Kras g12d 억제제를 포함하는 약학적 조성물 |
| WO2024032704A1 (en) | 2022-08-11 | 2024-02-15 | Beigene, Ltd. | Heterocyclic compounds, compositions thereof, and methods of treatment therewith |
| WO2024041573A1 (en) | 2022-08-25 | 2024-02-29 | Zai Lab (Shanghai) Co., Ltd. | Fused multi-heterocyclic compounds as kras g12d modulators and uses thereof |
| CN117771378A (zh) | 2022-09-29 | 2024-03-29 | 贝达药业股份有限公司 | 提高kras抑制剂生物利用度的药物组合及其应用 |
| EP4595963A4 (en) * | 2022-09-30 | 2026-01-21 | Inxmed Nanjing Co Ltd | PHARMACEUTICAL COMBINATION OF FAK INHIBITOR AND SUBSTANCE TO INDUCE IMMUNOGENEOUS CELL DEATH AND USE |
| TW202430182A (zh) * | 2022-12-14 | 2024-08-01 | 大陸商上海科州藥物研發有限公司 | 作為kras抑制劑的雜環化合物,及其製備和治療用途 |
| CN118221699A (zh) | 2022-12-20 | 2024-06-21 | 江苏恒瑞医药股份有限公司 | 一种kras g12d抑制剂的可药用盐、晶型及其制备方法 |
| TW202430184A (zh) | 2022-12-20 | 2024-08-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | Kras g12d抑制劑的結晶形式及製備方法 |
-
2023
- 2023-05-19 CN CN202380041256.4A patent/CN119365467A/zh active Pending
- 2023-05-19 EP EP23732731.7A patent/EP4526309A1/en active Pending
- 2023-05-19 CA CA3257445A patent/CA3257445A1/en active Pending
- 2023-05-19 IL IL316696A patent/IL316696A/en unknown
- 2023-05-19 JP JP2024568561A patent/JP7735594B2/ja active Active
- 2023-05-19 KR KR1020247041569A patent/KR20250013185A/ko active Pending
- 2023-05-19 AU AU2023272945A patent/AU2023272945A1/en active Pending
- 2023-05-19 US US18/199,449 patent/US20240025919A1/en not_active Abandoned
- 2023-05-19 WO PCT/US2023/022914 patent/WO2023225302A1/en not_active Ceased
- 2023-05-19 PE PE2024002607A patent/PE20250752A1/es unknown
- 2023-05-19 AR ARP230101266A patent/AR129388A1/es unknown
- 2023-05-19 CR CR20240508A patent/CR20240508A/es unknown
- 2023-05-19 TW TW112118800A patent/TW202400170A/zh unknown
-
2024
- 2024-05-28 US US18/676,200 patent/US12338256B2/en active Active
- 2024-10-25 ZA ZA2024/08076A patent/ZA202408076B/en unknown
- 2024-11-14 CL CL2024003491A patent/CL2024003491A1/es unknown
- 2024-11-15 MX MX2024014176A patent/MX2024014176A/es unknown
- 2024-12-17 CO CONC2024/0017330A patent/CO2024017330A2/es unknown
-
2025
- 2025-04-25 US US19/190,368 patent/US20260062425A1/en active Pending
- 2025-08-26 JP JP2025140269A patent/JP2026000916A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024506029A5 (cg-RX-API-DMAC7.html) | ||
| JP2024513881A5 (cg-RX-API-DMAC7.html) | ||
| MX2025002792A (es) | Inhibidores del gen homologo del virus del sarcoma de rata kirsten (g12d) | |
| RU2413727C2 (ru) | Производные пиразола и их применение в качестве ингибиторов рецепторных тирозинкиназ | |
| JP5865519B2 (ja) | イミダゾピロリジノン化合物 | |
| RU2365588C2 (ru) | Хиназолиновые соединения | |
| ES2364340T3 (es) | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. | |
| JP2022538228A5 (cg-RX-API-DMAC7.html) | ||
| RU2394826C2 (ru) | Дизамещенные пиразолобензодиазепины, используемые в качестве ингибиторов cdk2 и ангиогенеза, а также для лечения злокачественных новообразований молочной железы, толстого кишечника, легкого и предстательной железы | |
| JP2021526133A5 (cg-RX-API-DMAC7.html) | ||
| CA2437524A1 (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| SI20975B (sl) | N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/-karboksamidni inhibitorji ciklodekstrin odvisne kinaze | |
| AR129388A1 (es) | Compuestos aza-tetracíclicos de oxazepina y usos de los mismos | |
| RU2008112691A (ru) | Азотсодержащее гетероциклическое соединение и его фармацевтическое применение | |
| JP2021515010A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0918268B1 (pt) | Derivados de picolinamida, seu uso, e composição farmacêutica | |
| RU2005110656A (ru) | Ингибиторы tgf | |
| RU2003131693A (ru) | Новые ингибиторы тирозин киназ | |
| AR078187A1 (es) | Derivados heterociclicos de benzoxazepina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer. | |
| JP2004534010A5 (cg-RX-API-DMAC7.html) | ||
| JP2003525872A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0620058A2 (pt) | combinação farmacêutica compreendendo compostos inibidores da ligação da proteìna smac a proteìnas inibidoras de apoptose, e um taxano, bem como uso da mesma | |
| RU2006126974A (ru) | Амидное производное и лекарственное средство | |
| CA2494832A1 (en) | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | |
| RU2009126633A (ru) | Монофосфатные соединения, способ их получения, аэрозольный препарат (варианты) и способ профилактики и/или лечения бронхостеноза посредством указанных соединений |